POSSIBLE STORAGE OF CO₂ IN SALINE AQUIFER: STORAGE FACTOR ESTIMATION

The objective of this study is to perform laboratory measurements and a CO₂ underground storage study to cover the knowledge gap on CO₂-Brine relative permeability and assess various variables on the storage of CO₂ in a selected aquifer. Several factors that affect CO₂ storage have been discussed in the literature. These include both macroscopic and microscopic displacement efficiency of brine as a function of CO₂ pore volume injected. It is clear from the literature that there is still more work needed to investigate the effect of various variables such as formation temperature, brine viscosity, and the possible presence of free gas in the aquifer on the CO₂ storage efficiency of the selected aquifer. Experimental tests were conducted on four carbonate-limestone core samples to determine the capillary pressure curves and to conduct CO₂ flooding into 100% brine saturated core samples. Each core sample has with different brine salinity. Flooding tests were conducted at constant injection pressure yet, the injection temperature for each core sample was different. The brooks-Corey correlation was used to obtain the relative permeability curves of the CO₂ -Brine system. Using experimental results of capillary pressure, a modified Ritter and Drake correlation was used to determine the pore throat size distribution. This thesis research shows the results of limestone core flooding tests and CO₂ flooding of an aquifer runs obtained using Petroleum Solution software to evaluate the effect of brine viscosity, temperature, and gas saturation on aquifer CO₂ storage capacity (storage factor). The results revealed that the CO₂ storage capacity increases as temperature increases because of thermal effects. Whereas, as the gas saturation increases, the storage capacity of the selected zone decreases. In addition to that, the flooding runs showed that relatively high viscosity of brine aquifer hider the CO₂ storage capacity of the reservoir

Ecological basis of coevolutionary history

Journal ArticleMacroevolutionary patterns are difficult to interpret because they are the product of a time scale so vast that deterministic and chance events are hard to distinguish. Although the macroevolutionary history of a group can be reconstructed from extant species, determining the ecological context in which that group evolved is a tall order. Ecology involves interactions between organisms and both the living and nonliving components of their environments

Dex-CSDH randomised, placebo-controlled trial of dexamethasone for chronic subdural haematoma: report of the internal pilot phase.

The Dex-CSDH trial is a randomised, double-blind, placebo-controlled trial of dexamethasone for patients with a symptomatic chronic subdural haematoma. The trial commenced with an internal pilot, whose primary objective was to assess the feasibility of multi-centre recruitment. Primary outcome data collection and safety were also assessed, whilst maintaining blinding. We aimed to recruit 100 patients from United Kingdom Neurosurgical Units within 12 months. Trial participants were randomised to a 2-week course of dexamethasone or placebo in addition to receiving standard care (which could include surgery). The primary outcome measure of the trial is the modified Rankin Scale at 6 months. This pilot recruited ahead of target; 100 patients were recruited within nine months of commencement. 47% of screened patients consented to recruitment. The primary outcome measure was collected in 98% of patients. No safety concerns were raised by the independent data monitoring and ethics committee and only five patients were withdrawn from drug treatment. Pilot trial data can inform on the design and resource provision for substantive trials. This internal pilot was successful in determining recruitment feasibility. Excellent follow-up rates were achieved and exploratory outcome measures were added to increase the scientific value of the trial.NIHR HT

A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)

Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 13/15/02) and is published in full in Health Technology Assessment; Vol. 28, No. 12. See the NIHR Funding and Awards website for further award information.Peer reviewe

Decompressive craniectomy versus craniotomy for acute subdural hematoma

BACKGROUND: Traumatic acute subdural hematomas frequently warrant surgical evacuation by means of a craniotomy (bone flap replaced) or decompressive craniectomy (bone flap not replaced). Craniectomy may prevent intracranial hypertension, but whether it is associated with better outcomes is unclear. METHODS: We conducted a trial in which patients undergoing surgery for traumatic acute subdural hematoma were randomly assigned to undergo craniotomy or decompressive craniectomy. An inclusion criterion was a bone flap with an anteroposterior diameter of 11 cm or more. The primary outcome was the rating on the Extended Glasgow Outcome Scale (GOSE) (an 8-point scale, ranging from death to “upper good recovery” [no injury-related problems]) at 12 months. Secondary outcomes included the GOSE rating at 6 months and quality of life as assessed by the EuroQol Group 5-Dimension 5-Level questionnaire (EQ-5D-5L). RESULTS: A total of 228 patients were assigned to the craniotomy group and 222 to the decompressive craniectomy group. The median diameter of the bone flap was 13 cm (interquartile range, 12 to 14) in both groups. The common odds ratio for the differences across GOSE ratings at 12 months was 0.85 (95% confidence interval, 0.60 to 1.18; P=0.32). Results were similar at 6 months. At 12 months, death had occurred in 30.2% of the patients in the craniotomy group and in 32.2% of those in the craniectomy group; a vegetative state occurred in 2.3% and 2.8%, respectively, and a lower or upper good recovery occurred in 25.6% and 19.9%. EQ-5D-5L scores were similar in the two groups at 12 months. Additional cranial surgery within 2 weeks after randomization was performed in 14.6% of the craniotomy group and in 6.9% of the craniectomy group. Wound complications occurred in 3.9% of the craniotomy group and in 12.2% of the craniectomy group. CONCLUSIONS: Among patients with traumatic acute subdural hematoma who underwent craniotomy or decompressive craniectomy, disability and quality-of-life outcomes were similar with the two approaches. Additional surgery was performed in a higher proportion of the craniotomy group, but more wound complications occurred in the craniectomy group. (Funded by the National Institute for Health and Care Research; RESCUE-ASDH ISRCTN Registry number, ISRCTN87370545.

Molecular Signatures of Prostate Stem Cells Reveal Novel Signaling Pathways and Provide Insights into Prostate Cancer

BACKGROUND:The global gene expression profiles of adult and fetal murine prostate stem cells were determined to define common and unique regulators whose misexpression might play a role in the development of prostate cancer. METHODOLOGY/PRINCIPAL FINDINGS:A distinctive core of transcriptional regulators common to both fetal and adult primitive prostate cells was identified as well as molecules that are exclusive to each population. Elements common to fetal and adult prostate stem cells include expression profiles of Wnt, Shh and other pathways identified in stem cells of other organs, signatures of the aryl-hydrocarbon receptor, and up-regulation of components of the aldehyde dehydrogenase/retinoic acid receptor axis. There is also a significant lipid metabolism signature, marked by overexpression of lipid metabolizing enzymes and the presence of the binding motif for Srebp1. The fetal stem cell population, characterized by more rapid proliferation and self-renewal, expresses regulators of the cell cycle, such as E2f, Nfy, Tead2 and Ap2, at elevated levels, while adult stem cells show a signature in which TGF-beta has a prominent role. Finally, comparison of the signatures of primitive prostate cells with previously described profiles of human prostate tumors identified stem cell molecules and pathways with deregulated expression in prostate tumors including chromatin modifiers and the oncogene, Erg. CONCLUSIONS/SIGNIFICANCE:Our data indicate that adult prostate stem or progenitor cells may acquire characteristics of self-renewing primitive fetal prostate cells during oncogenesis and suggest that aberrant activation of components of prostate stem cell pathways may contribute to the development of prostate tumors

Project Glass: Google’s Augmented Reality Glasses

Technology is everywhere. It is very beneficial and plays a big role in our lives today. But it controls the way people collaborate with each other in our work, studies, mobility, communication, thinking, and even our eating. We believe technology “should work for you—to be there when you need it and get out of your way when you don’t [1]. “ And here comes the role of Google Glass as an alternative. The project was started by the Google company under the name ‘Project Glass’ to create a significant type of technology that provides an environment to help people share the world and put it back in the moment. Google Glass is an augmented reality head-mounted display (HMD) developed by Google within Project Glass’ research & development program [2]. Our focus in this marketing plan will be on enterprise businesses, rather than only solutions for individual end users. Google is already in the enterprise market. We will go through our marketing plan by starting with the product itself, and by doing a Product Analysis. We discuss a Technology Assessment and then explore the product propose, components, features, and value it can provide to enterprise customers. Then we will go through our Market Analysis to show our potential customer segmentations. We explain our decision of choosing our targeted early adapters and early majority and illustrate the technology’s adoption lifecycle curve and crossing the chasm. Later on, in the Customer Analysis section we explain our targeted customers in depth by giving a definition and exploring their activities. We show the role of Google Glass in the work process and end up with the customer perceptions. Furthermore, in the Competitor Analysis section, we will create a competitive landscape to map our product’s competitors by giving an in-depth elaboration on every competitor’s pros and cons and their place in the landscape position. The competitor section is finished by doing a SWOT analysis to show our organization’s points of strengths, weaknesses; current and potential opportunities and source of threats. Moreover, in the Market Strategy we’ll talk about positioning, promotion, and distribution. Following this further, in the Finance section we’ll illustrate the product pricing, costs, and revenues. In the same way we’ll show our revenue allocation estimates, expenses budget, and finish with customer value pricing

Cost-effectiveness of craniotomy versus decompressive craniectomy for UK patients with traumatic acute subdural haematoma.

Peer reviewed: TrueOBJECTIVE: To estimate the cost-effectiveness of craniotomy, compared with decompressive craniectomy (DC) in UK patients undergoing evacuation of acute subdural haematoma (ASDH). DESIGN: Economic evaluation undertaken using health resource use and outcome data from the 12-month multicentre, pragmatic, parallel-group, randomised, Randomised Evaluation of Surgery with Craniectomy for Patients Undergoing Evacuation-ASDH trial. SETTING: UK secondary care. PARTICIPANTS: 248 UK patients undergoing surgery for traumatic ASDH were randomised to craniotomy (N=126) or DC (N=122). INTERVENTIONS: Surgical evacuation via craniotomy (bone flap replaced) or DC (bone flap left out with a view to replace later: cranioplasty surgery). MAIN OUTCOME MEASURES: In the base-case analysis, costs were estimated from a National Health Service and Personal Social Services perspective. Outcomes were assessed via the quality-adjusted life-years (QALY) derived from the EuroQoL 5-Dimension 5-Level questionnaire (cost-utility analysis) and the Extended Glasgow Outcome Scale (GOSE) (cost-effectiveness analysis). Multiple imputation and regression analyses were conducted to estimate the mean incremental cost and effect of craniotomy compared with DC. The most cost-effective option was selected, irrespective of the level of statistical significance as is argued by economists. RESULTS: In the cost-utility analysis, the mean incremental cost of craniotomy compared with DC was estimated to be -£5520 (95% CI -£18 060 to £7020) with a mean QALY gain of 0.093 (95% CI 0.029 to 0.156). In the cost-effectiveness analysis, the mean incremental cost was estimated to be -£4536 (95% CI -£17 374 to £8301) with an OR of 1.682 (95% CI 0.995 to 2.842) for a favourable outcome on the GOSE. CONCLUSIONS: In a UK population with traumatic ASDH, craniotomy was estimated to be cost-effective compared with DC: craniotomy was estimated to have a lower mean cost, higher mean QALY gain and higher probability of a more favourable outcome on the GOSE (though not all estimated differences between the two approaches were statistically significant). ETHICS: Ethical approval for the trial was obtained from the North West-Haydock Research Ethics Committee in the UK on 17 July 2014 (14/NW/1076). TRIAL REGISTRATION NUMBER: ISRCTN87370545